Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
UTC Therapeutics Inc.
Beijing Friendship Hospital
NGM Biopharmaceuticals, Inc
Centre Hospitalier Universitaire Vaudois
Zhejiang University
Multitude Therapeutics Inc.
Kineta Inc.
Shanghai Yunying Medical Technology
Wuhan Ammunition Life-tech Co., Ltd
Blue Note Therapeutics
Revolution Medicines, Inc.
Imperial College London
Assistance Publique - Hôpitaux de Paris
Weprom
Shanghai Fengxian District Central Hospital
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Samyang Biopharmaceuticals Corporation
Shenzhen BinDeBio Ltd.
University of Magdeburg
Bay Area Gynecology Oncology
Critical Outcome Technologies Inc.
Xuanwu Hospital, Beijing
Quantgene Inc.
Merrimack Pharmaceuticals
SPGO Research Mannheim GmbH
Shenzhen Second People's Hospital
Chinese PLA General Hospital
Alaunos Therapeutics
Instituto de Investigação em Imunologia
Poniard Pharmaceuticals